Morgan Stanley Maintains Overweight on Trevi Therapeutics, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Negative 81.7%

Neg 81.7% Neu 0% Pos 0%

Morgan Stanley analyst Judah Frommer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and lowers the price target from $19 to $18.